Targeting T cells to tumor cells using bispecific antibodies.

Targeting T cells to tumor cells using bispecific antibodies.
Curr Opin Chem Biol. 2013 Apr 25;
Authors: Frankel SR, Baeuerle PA
Abstract
The immune system, and in particular T cells, can be harnessed to treat cancer. Several bispecific T cell engaging antibodies of the BiTE(®) format are in early or late-stage clinical development. These small recombinant antibody constructs effectively trigger killing of cancer cells by temporarily attached, polyclonal T cells. Blinatumomab, a CD19/CD3-bispecific BiTE(®) antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. Three additional BiTE antibodies directed against surface target antigen expressed on solid tumors are being evaluated in phase I clinical trials. Alternative approaches to direct polyclonal T cells to kill cancer cells are under intense investigation.
PMID: 23623807 [PubMed - as supplied by publisher]

Source: Current Opinion in Chemical Biology - April 25, 2013 Category: Biochemistry Authors: Frankel SR, Baeuerle PA Tags: Curr Opin Chem Biol Source Type: research